stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Free cash flow
Denali Therapeutics Inc.'s free cash flow for fiscal 2025 was −$422.1M, compared with −$363.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$450.0M. Over the past ten years it has ranged from −$422.1M (fiscal 2025) to $413.1M (fiscal 2020) — the current reading is the lowest in ten years. Denali Therapeutics Inc. ranks 585th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$422.1M | — |
| FY2024 | −$363.6M | — |
| FY2023 | −$370.9M | — |
| FY2022 | −$262.5M | — |
| FY2021 | −$219.9M | — |
| FY2020 | $413.1M | — |
| FY2019 | −$169.5M | — |
| FY2018 | $46.7M | — |
| FY2017 | −$79.5M | — |
| FY2016 | −$78.0M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$118.5M | — |
| Jun 2026 | −$97.8M | — |
| Mar 2026 | −$133.7M | — |
| Dec 2025 | −$100.1M | — |
| 37 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | $32.4M |
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| ELVN Enliven Therapeutics, Inc. compare | −$67.0M |
| CELC Celcuity, Inc. compare | −$192.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$349.8M |
| DNLI Denali Therapeutics Inc. | −$450.0M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
| DYN Dyne Therapeutics, Inc. compare | −$480.4M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement